This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...